GF Fund Management CO. LTD. Invests $331,000 in United Therapeutics Co. (NASDAQ:UTHR)

GF Fund Management CO. LTD. bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 937 shares of the biotechnology company's stock, valued at approximately $331,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cerity Partners LLC raised its position in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the last quarter. Milestone Asset Management LLC boosted its position in shares of United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Korea Investment CORP increased its holdings in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after acquiring an additional 789 shares during the period. Finally, Pacer Advisors Inc. boosted its position in United Therapeutics by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock worth $210,869,000 after purchasing an additional 30,931 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,500 shares of company stock worth $13,447,180. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 1.5%

Shares of NASDAQ UTHR traded up $4.73 during midday trading on Thursday, hitting $320.37. The stock had a trading volume of 481,516 shares, compared to its average volume of 442,758. United Therapeutics Co. has a 1-year low of $264.33 and a 1-year high of $417.82. The company has a market capitalization of $14.45 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.97 and a beta of 0.58. The company has a fifty day moving average price of $299.49 and a 200 day moving average price of $336.45.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the company posted $6.17 earnings per share. United Therapeutics's revenue was up 17.2% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on UTHR. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley lifted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a report on Monday, April 21st. JPMorgan Chase & Co. cut their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $392.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.